Answers are grounded in this paper and cite their sources.
Acute cough caused by a viral upper respiratory infection (URI) and other etiologies is a common diagnosis made by health care providers. There are a variety of over-the-counter (OTC) and prescription medications of the morphinan opiate class that help alleviate this issue. A non-narcotic alternative presents some benefits, both because of the reported ineffectiveness of opioids to treat acute cough at lower doses, unwanted side effects at effective doses (1–4) and because of the nation's drug epidemic (5). Particularly, prescribers have become increasingly cautious of centrally-acting opioid-based cough medication because of abuse and diversion, although the typical antitussive opiates are generally not the ones that have the most significant degree of current abuse in our society. Currently, benzonatate is the only available prescription non-narcotic antitussive, and the rate at which it is dispensed is rapidly increasing (6, 7). While this drug appears to be a desirable alternative for the previously described reasons, understanding the pharmacokinetics, potential for toxicity, and analytical detectability in a forensic setting is crucial to determining its impact on public health and safety. Benzonatate (Tessalon® Perles) was approved in 1958 as a peripherally-acting antitussive for its ability to inhibit cough before its mechanism of action was completely understood. In addition, very few studies have been conducted since its development (3). Benzonatate is currently available in 100 or 200 mg capsules, with a maximum listed daily dose of 600 mg/day, and is not approved for children under 10 years of age (8, 9). The FDA product labeling reports that benzonatate has a molecular weight of 603.7 g/mol with a side chain of nine ethoxy units. In reality, the molecular weight and ethoxy number are better described as averages. Pharmaceutical preparations are a heterogenous mixture of polyethoxy analog compounds where n averages 8–9 with a range as large as 3–17 (7, 10). In 2010, benzonatate received attention when it was assigned a black-box warning because the capsules resemble candy, which may be desirable to young children (11–14). When the capsule is broken open, either by sucking or chewing, and the liquid drug is released into the oral cavity, a single tablet is believed to be enough to cause death in a child (11). McLawhorn et al. describe fatalities in 20 of the 31 overdose cases reported to the FDA Adverse Event Reporting System (AERS), recognizing a rapid onset of symptoms (within 1 h) and a relatively low margin for safety (6). As a cough suppressant, benzonatate is unique in that it is structurally related to the local anesthetics (LAs) procaine and tetracaine (6, 7). Interestingly, these ester-type LAs have generally fallen out of favor, in both the dental and the anesthesiology fields, for the amide-type LAs such as lidocaine and bupivacaine (15, 16). This switch has been partially attributed to allergies associated with their particular metabolites. Unusual reactions to p-aminobenzoic acid (PABA)-derived ester-based LAs have been associated with these underlying allergies; however, the incidence of true IgE-mediated reactions is unknown and presumed to be rare (15–18). Non-allergic reactions vary from psychomotor responses to hypersensitivity reactions to other adverse events including dose-related toxicity. Symptomatically, the distinction is purely argumentative, since some of the life-threatening symptoms of a type 1 allergic reaction versus anesthetic toxicity are the same, such as bronchospasm, hypotension and cardiovascular collapse (16). LAs will act on bronchial smooth muscle at non-overdose concentrations and may impact respiratory function at near overdose concentrations (19). Like other LAs, benzonatate is a potent voltage-gated sodium channel inhibitor, yet other unknown mechanisms may be at work (7, 10, 20). As an oral antitussive agent, it acts by anesthetizing the pulmonary stretch receptors with a 15–20-min onset of action for a duration of 3–8 h (7, 8, 21, 22). Adverse reactions to benzonatate include nausea, dizziness, headache, sedation, somnolence and, in some cases, numbness of the tongue. Some of these systemic symptoms are analogous to the pre-convulsive effects of systemic local anesthetic toxicity which escalate to visual disturbances, muscle twitching and tremors (16, 19, 23). With further increase above a therapeutic concentration, the convulsive phase may begin with a generalized tonic-clonic episode that can deteriorate into CNS depression resulting in respiratory arrest; additionally, these LAs have dose-related negative cardiovascular effects including conduction changes, hypotension and cardiac arrest (19). Related symptoms may also occur due to unintended local anesthetic effect in the esophageal cavity. When a therapeutic dose, administered as a single capsule, is chewed or crushed, there is potential for bronchospasm, laryngospasm, seizures and cardiovascular collapse which mimics the systemic toxicity seen at high doses (6, 15, 19, 20). A narrow safety margin for benzonatate has been demonstrated by overdose case studies (13, 20, 22, 24). In several of the published over-ingestion cases, as well as those observed in our office, only a small handful of pills was enough to cause seizures, a cardiac event and death. Interestingly, the product insert directs one to not double up a missed dose of benzonatate and only take a maximum of 200 mg at a time. Blood data is inconclusive or unavailable in the majority of death cases (6, 10), however fatalities have been reported with blood concentrations of 5 and 35 mg/L (9, 22). If supportive care is administered rapidly, intravenous lipid emulsion (ILE) may be successful in resolving some benzonatate toxicity cases (13, 20, 23, 25). Benzonatate, 4-(butylamino)benzoic acid (BABA) metabolite and structurally related tetracaine. Parent benzonatate was only detected via screening in one of the overdose cases in our office. It appeared as a late-eluting compound after trazodone in the base screen and was quantitated by a reference laboratory using traditional HPLC methodology. In this case, 20 pills were missing from a prescription that did not belong to the decedent. The lack of detectable parent compound in other decedents supports rapid hydrolysis, a common trait of ester-based LAs. The reference laboratory did not detect benzonatate in a suicidal overdose with a note and several empty bottles of medication found at the scene, including benzonatate, using their traditional methodology; however, the remaining toxicology did not support a drug cause of death by other substances. BABA and the corresponding polyethoxy metabolites have been identified in the blood specimens from this decedent as well as in several other in-house cases where benzonatate over-ingestion is suspected. Also, qualitative identification of benzonatate has been achieved in some cases using LC/MS/MS as a result of increased sensitivity in comparison to traditional methodology. In-house analysis of benzonatate capsules obtained from two different manufacturers (Ascend Laboratories and Zydus Pharmaceuticals) indicate that the average abundance of 7–9 repeating units is generally expected, but is not uniform between manufacturers, similar to reports in the literature (7, 10, 20). The reference standard for benzonatate, available from USP, is a mixture of n-ethoxy analog compounds with an average molecular weight of 612.23 g/mol (28). Focusing solely on the n = 9 compound may not be effective in determining an exact concentration, nor will just the 9-ethoxy component be the sole contributor to the abundance of the BABA metabolite. Evans et al. have demonstrated the inability of the BABA metabolite to block voltage-gated sodium currents at 100 µM, and other mechanisms may be at work; however, this metabolite will be the best candidate for detection of benzonatate exposure (7, 21). Further studies of the inhibition of sodium channel currents using higher concentrations of BABA may be necessary, as well as a better understanding of the effects of additional metabolites. Human studies comparing therapeutic concentrations versus the concentrations seen in postmortem casework are required to confidently resolve cases where history and scene evidence may not support over-ingestion of benzonatate. The pseudocholinesterase deficient portion of the population may be prone to increased sensitivities of this cough medication (16) because of diminished ability to hydrolyze the parent compound and thus potential prolongation of increased benzonatate activity. Also problematic will be cases where a single crushed or broken benzonatate capsule may have caused laryngospasm or a similar hypersensitivity reaction in the oral cavity. Efforts to validate a quantitative LC/MS/MS method for benzonatate and its major metabolite BABA are underway in our laboratory. Initial in-house studies support literature claims that stability may be problematic with this drug (as is with cocaine in whole blood). Even more challenging is the rapid metabolism of the series of n-ethoxy parent compounds without a suitable pure standard available for quantitation of each specific molecular weight. Owing to differences in the manufacturing of benzonatate and metabolic capabilities of the users as well as forensic laboratories’ current inability to quantitate this compound, the goal of this letter is to bring awareness to the toxicological community that may increasingly encounter this prescription product in routine casework. Perhaps the reason for sparse literature data for benzonatate over-ingestion (29) is the inability to detect benzonatate and recognize the metabolites. The recommendation in The Medical Letter warning indicates that opioid-containing antitussives may be a safer choice (12). Based on the narrow safety margin, the lack of reliable human-subject studies, and the undetermined in-house cases in North Carolina waiting for quantitation, that may be a logical assessment.
No takes yet. Share an insight, caveat, or question.
Bishop-Freeman et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: